These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38369125)

  • 1. Monotherapy vs combination therapy in patients with Klebsiella pneumoniae bloodstream infection: A systematic review and meta-analysis.
    Li D; Rao H; Xu Y; Zhang M; Zhang J; Luo J
    J Infect Chemother; 2024 May; 30(5):372-378. PubMed ID: 38369125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistin monotherapy or combination for the treatment of bloodstream infection caused by Klebsiella pneumoniae: a systematic review and meta-analysis.
    Wang T; Liu H; Huang H; Weng Y; Wang X
    BMC Infect Dis; 2024 Feb; 24(1):161. PubMed ID: 38317132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
    Vieceli T; Henrique LR; Rech TH; Zavascki AP
    J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
    Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
    Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
    Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant
    Sun WM; Zhou H; Shen LS; Yang Q; Ma WJ; Zhou JY
    Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):566-571. PubMed ID: 31365977
    [No Abstract]   [Full Text] [Related]  

  • 8. Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis.
    Kohler PP; Volling C; Green K; Uleryk EM; Shah PS; McGeer A
    Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1319-1328. PubMed ID: 28950924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China.
    Li Y; Li J; Hu T; Hu J; Song N; Zhang Y; Chen Y
    Antimicrob Resist Infect Control; 2020 Jun; 9(1):79. PubMed ID: 32487221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.
    Geng TT; Xu X; Huang M
    Medicine (Baltimore); 2018 Feb; 97(8):e9961. PubMed ID: 29465589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
    Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
    J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant
    Chen J; Xia B; Liu Y; Sun W; Liu F; Pang J; Cheng H
    Ann Med; 2024 Dec; 56(1):2397087. PubMed ID: 39239861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients.
    Zhang Y; Guo LY; Song WQ; Wang Y; Dong F; Liu G
    BMC Infect Dis; 2018 May; 18(1):248. PubMed ID: 29855274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis.
    Vardakas KZ; Mavroudis AD; Georgiou M; Falagas ME
    Int J Antimicrob Agents; 2018 Apr; 51(4):535-547. PubMed ID: 29288723
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Li D; Huang X; Rao H; Yu H; Long S; Li Y; Zhang J
    Front Cell Infect Microbiol; 2023; 13():1157010. PubMed ID: 37153146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
    Qureshi ZA; Paterson DL; Potoski BA; Kilayko MC; Sandovsky G; Sordillo E; Polsky B; Adams-Haduch JM; Doi Y
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2108-13. PubMed ID: 22252816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors for the Development of Colistin Resistance during Colistin Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
    Huang PH; Chen WY; Chou SH; Wang FD; Lin YT
    Microbiol Spectr; 2022 Jun; 10(3):e0038122. PubMed ID: 35652641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
    Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
    Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
    Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias.
    Micozzi A; Gentile G; Minotti C; Cartoni C; Capria S; Ballarò D; Santilli S; Pacetti E; Grammatico S; Bucaneve G; Foà R
    BMC Infect Dis; 2017 Mar; 17(1):203. PubMed ID: 28283020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.